Abiraterone in metastatic salivary duct carcinoma.
Abiraterone in metastatic salivary duct carcinoma.
复制标题
阿比特龙治疗转移性唾液管癌。
DOI：
10.6004/jnccn.2015.0040
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
B. Solomon
中科院分区：
文献类型：
--
作者：
D. Urban;D. Rischin;C. Angel;I. D'Costa;B. Solomon
涎腺导管癌（SDC）是一种罕见的、侵袭性的涎腺恶性肿瘤，指导标准治疗的证据有限。已知SDC过度表达雄激素受体，只有少数病例报告对雄激素阻断有反应。本报告介绍了一个SDC对多种雄激素阻断药物有反应的病例，包括对阿比特龙（一种对前列腺癌有效的CYP17抑制剂）的快速反应。该病例是首次发表的SDC对阿比特龙有反应的报告，并说明表达雄激素受体的SDC可以用多种雄激素阻断剂治疗，包括较新的药物，如阿比特龙。本病例提示SDC在雄激素剥夺进展后可能继续依赖雄激素，这类似于前列腺癌。
Salivary duct carcinoma (SDC) is a rare, aggressive salivary gland malignancy with limited evidence guiding standard treatment. SDC is known to overexpress the androgen receptor, with only a handful of cases reporting responses to androgen blockade. This report presents a case of SDC responding to multiple lines of androgen blockade, including a rapid response to abiraterone, a CYP17 inhibitor effective in prostate cancer. This case represents the first published report of SDC responding to abiraterone and illustrates that androgen receptor expressing SDC may be treated with multiple lines of androgen blockade, including newer agents such as abiraterone. This case suggests that SDC may continue to be androgen-dependent after progression on androgen deprivation, which is analogous to prostate cancer.
DOI：
10.1056/nejmoa1014618
发表时间：
2011-05-26
期刊：
The New England journal of medicine
影响因子：
--
作者：
de Bono JS;Logothetis CJ;Molina A;Fizazi K;North S;Chu L;Chi KN;Jones RJ;Goodman OB Jr;Saad F;Staffurth JN;Mainwaring P;Harland S;Flaig TW;Hutson TE;Cheng T;Patterson H;Hainsworth JD;Ryan CJ;Sternberg CN;Ellard SL;Fléchon A;Saleh M;Scholz M;Efstathiou E;Zivi A;Bianchini D;Loriot Y;Chieffo N;Kheoh T;Haqq CM;Scher HI;COU-AA-301 Investigators
通讯作者：
COU-AA-301 Investigators
影响因子：
11.2
作者：
Montgomery, R. Bruce;Mostaghel, Elahe A.;Nelson, Peter S.
通讯作者：
Nelson, Peter S.